# 2025年12月13日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 使用利福昔明的肝硬化伴肝性脑病患者具有更高的抗菌药耐药风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381601)
**期刊：** Nature communications
**PMID：** 41381601
**DOI：** 10.1038/s41467-025-67326-y

### 第一部分 原文与翻译

**英文原标题：** Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin.

> **英文摘要：**
> Rifaximin, a non-absorbable antibiotic used in managing recurrent hepatic encephalopathy (HE), has traditionally been considered low risk for inducing resistance. However, emerging evidence raised concerns that widespread rifaximin use may promote antimicrobial resistance (AMR). In this multi-national retrospective cohort study, we evaluate the association between rifaximin use and subsequent AMR in patients with cirrhosis and HE. After propensity score matching for 78 covariates, hazard ratios (HRs) and 95% confidence intervals (CIs) for AMR and infection-related adverse events are calculated for the one-year follow-up. We demonstrate a two-fold AMR risk associated with rifaximin use (HR = 1.89; 95% CI = 1.49-2.40), with significantly increased risks of vancomycin resistance (HR = 2.52; 95% CI = 1.64-3.88) and multidrug resistance (HR = 2.31; 95% CI = 1.38-3.85). Rifaximin use is also associated with an escalated risk of sepsis, spontaneous bacterial peritonitis, and the use of last-line antibiotics. Notably, patients receiving other antibiotics prior to rifaximin treatment exhibit greater AMR risks. These findings challenge the conventional view of rifaximin as a low-risk intervention and support mechanistic evidence linking rifaximin exposure to cross-resistance against critical antibiotics with real-world evidence.

> **中文摘要：**
> 利福昔明是一种不可吸收的抗生素，用于治疗复发性肝性脑病（HE），传统上被认为诱导耐药的风险较低。然而，新的证据引发了广泛使用利福昔明可能促进抗菌药耐药性（AMR）的担忧。在这项多国回顾性队列研究中，我们评估了利福昔明的使用与肝硬化及肝性脑病患者后续AMR发生之间的关联。通过对78个协变量进行倾向评分匹配后，我们计算了一年随访期内AMR及感染相关不良事件的风险比（HR）及95%置信区间（CI）。结果显示，利福昔明使用与约两倍的AMR风险相关（HR = 1.89；95% CI = 1.49–2.40），并显著增加了万古霉素耐药（HR = 2.52；95% CI = 1.64–3.88）和多重耐药（HR = 2.31；95% CI = 1.38–3.85）的风险。利福昔明的使用还与脓毒症、自发性细菌性腹膜炎及使用末线抗生素的风险升高相关。值得注意的是，在利福昔明治疗前使用过其他抗生素的患者表现出更高的AMR风险。这些发现挑战了将利福昔明视为低风险干预的传统观点，并以真实世界证据支持了利福昔明暴露与关键抗生素交叉耐药的机制关联。

### 第二部分 AI 大师评价

该研究基于多国回顾性队列，系统评估了利福昔明使用与肝硬化伴肝性脑病患者抗菌药耐药发生的关联。研究采用倾向评分匹配控制混杂因素，揭示了利福昔明使用与AMR、万古霉素耐药及多重耐药风险均显著升高。该结果挑战了以往将利福昔明视为低耐药风险药物的观点，提示临床在长期用药中需权衡风险和获益。研究创新性地以跨国真实世界数据提供了抗生素交叉耐药的实证支持，但仍受限于观察性研究的固有偏倚与因果推断不足。

---

## 2. 转录因子与 cBAF 的共凝聚选择性调控染色质重塑与基因表达

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381493)
**期刊：** Nature communications
**PMID：** 41381493
**DOI：** 10.1038/s41467-025-67322-2

### 第一部分 原文与翻译

**英文原标题：** Co-condensation between transcription factor and cBAF selectively modulates chromatin remodeling and gene expression.

> **英文摘要：**
> Activation of gene transcription is a tightly coordinated process that requires the engagement of transcription factors (TFs) and chromatin remodelers, yet how these components integrate at specific genomic loci remains unclear. Here, we report that ARID1A, a key subunit of the chromatin remodeler cBAF complex, forms condensates through uniformly distributed tyrosine residues within its core intrinsically disordered region (IDR). A series of TFs which feature in the presence of tyrosine within their transcription activation domain (TAD), selectively interact with ARID1A through core IDR-TAD interaction, thereby enabling co-condensation at specific loci. Furthermore, we demonstrate that co-condensation between ARID1A and TFs, such as GATA2, is crucial for maintaining chromatin accessibility and activating genes essential for lung cancer cell proliferation. Collectively, our study establishes the essential role of ARID1A in spatial organization of TFs and cBAF through phase separation, and demonstrates that tyrosine-mediated selective TFs-cBAF co-condensation represents a pivotal mechanism for gene activation.

> **中文摘要：**
> 基因转录的激活是一个高度协调的过程，需要转录因子（TFs）与染色质重塑因子的参与，但这些组成部分如何在特定基因组位点上整合仍不清楚。在此，我们报道了染色质重塑复合物 cBAF 的关键亚基 ARID1A 能通过其核心固有无序区（IDR）中均匀分布的酪氨酸残基形成凝聚体。一系列在其转录激活结构域（TAD）中含有酪氨酸的转录因子可通过核心 IDR–TAD 相互作用选择性地与 ARID1A 结合，从而在特定位点实现共凝聚。此外，我们证实 ARID1A 与转录因子（如 GATA2）之间的共凝聚对于维持染色质可及性并激活对肺癌细胞增殖至关重要的基因具有关键作用。综上所述，本研究阐明了 ARID1A 通过液‑液相分离在空间上组织转录因子与 cBAF 的关键作用，并表明由酪氨酸介导的选择性 TFs‑cBAF 共凝聚是基因激活的关键机制。

### 第二部分 AI 大师评价

本研究揭示了 ARID1A 作为 cBAF 复合物核心亚基在介导转录因子与染色质重塑之间空间协调的关键作用。作者利用分子相分离机制，阐明了酪氨酸残基驱动的 ARID1A 与含酪氨酸的转录因子之间的选择性共凝聚，从而调控染色质可及性与基因激活。该工作创新性地建立了 TF‑cBAF 相分离模型，为理解转录调控与肿瘤发生提供了新的分子机制。其局限在于主要基于体外和特定细胞系实验，仍需在原位、时空尺度上进一步验证。

---

## 3. 炎症条件下无义突变CFTR氯离子通道的功能恢复显著改善

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381228)
**期刊：** The European respiratory journal
**PMID：** 41381228
**DOI：** 10.1183/13993003.01171-2025

### 第一部分 原文与翻译

**英文原标题：** Rescue of the CFTR chloride channel with nonsense mutations is markedly improved under inflammatory conditions.

> **英文摘要：**
> Loss of CFTR chloride channel function is the basic defect in cystic fibrosis (CF), a genetic disease that particularly affects the respiratory system, with bacterial infection and severe inflammation. People with CF carrying the most frequent mutation (F508del) or many types of missense mutations can be efficiently treated with drugs, named correctors and potentiators, that improve CFTR protein processing and channel activity. These treatments are ineffective on nonsense mutations that lead to nonsense-mediated RNA decay (NMD) and CFTR protein truncation. We tested the efficacy of a triple combination of small molecules including the readthrough agent ELX-02, the CFTR corrector VX-809, and the eRF3A degrader CC-90009, on cultured airway epithelia from patients carrying the G542X mutation. The treatment resulted in a significant but relatively modest (three-fold) increase in CFTR function. Importantly, the efficacy of the triple drug combination was greatly amplified under inflammatory conditions,  by exposing the epithelia to IL-4 (15-fold increase) or to IL-17A/TNF-α (9-fold increase). Similar effects were also found in epithelia with the W1282X mutation. The large rescue of CFTR function under inflammatory conditions was paralleled by the appearance of full-length CFTR protein and by the increase in CFTR mRNA. The effect of inflammatory stimuli could be mediated by enhanced translational readthrough and/or reduced NMD. Our results suggest that rescue of CFTR with nonsense mutations could be more effective than expected  Our findings may also lead to the identification of novel targets to correct the effect of nonsense mutations in CF and other genetic diseases.

> **中文摘要：**
> CFTR氯离子通道功能缺失是囊性纤维化（CF）的基本缺陷，这是一种遗传性疾病，特别累及呼吸系统，并伴有细菌感染和严重炎症。携带最常见突变（F508del）或多种错义突变的CF患者，可通过称为“矫正剂”和“增强剂”的药物有效治疗，这些药物能改善CFTR蛋白的加工和通道活性。然而，这些治疗对导致无义介导的RNA降解（NMD）及CFTR蛋白截断的无义突变无效。我们在携带G542X突变患者来源的培养气道上皮细胞中，测试了包括翻译读通剂ELX-02、CFTR矫正剂VX-809和eRF3A降解剂CC-90009在内的三联小分子组合的疗效。该治疗导致CFTR功能显著但相对温和的三倍提升。值得注意的是，在炎症条件下，通过将上皮暴露于IL-4（功能提升15倍）或IL-17A/TNF-α（提升9倍），三联药物组合的疗效显著增强。在携带W1282X突变的上皮中也观察到了类似效应。在炎症条件下CFTR功能的大幅恢复伴随着全长CFTR蛋白的出现及CFTR mRNA水平的增加。炎症刺激的作用可能通过增强翻译读通和/或减少NMD实现。我们的结果提示，无义突变型CFTR的功能恢复可能比预期更为有效。我们的研究结果还可能有助于识别新的靶点，用以纠正CF及其他遗传病中无义突变的影响。

### 第二部分 AI 大师评价

该研究旨在探索炎症条件对无义突变型CFTR功能恢复的影响。研究采用ELX-02、VX-809及CC-90009三联小分子组合，在携带G542X或W1282X突变的气道上皮模型中进行验证。结果显示，在IL-4或IL-17A/TNF-α诱导的炎症环境下，CFTR功能恢复显著增强，并伴随蛋白及mRNA水平的提升。研究揭示炎症状态可能通过促进读通或抑制NMD增强治疗效果，提示利用炎症信号通路可能成为无义突变CF个体的潜在治疗策略，但其临床可行性与安全性仍需进一步验证。

---

## 4. 人工智能在特发性肺纤维化中的应用：进展、挑战与未来方向

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381227)
**期刊：** The European respiratory journal
**PMID：** 41381227
**DOI：** 10.1183/13993003.01112-2025

### 第一部分 原文与翻译

**英文原标题：** Artificial Intelligence in Idiopathic Pulmonary Fibrosis: Advances, Challenges, and Future Directions.

> **英文摘要：**
> Idiopathic Pulmonary Fibrosis (IPF) is a progressive disease of unknown etiology, characterized by a radiological and/or morphological pattern of usual interstitial pneumonia. Its diagnosis is challenging, and disease progression is often variable and unpredictable. In recent years the introduction of Artificial Intelligence (AI), particularly machine-learning (ML) and deep-learning (DL) models, has shown the potential to improve the diagnosis, prognosis, and therapeutic strategies for IPF. As part of DL, convolutional neural network, enhance the accuracy of high-resolution computed tomography analysis, facilitating early and precise diagnosis. Likewise, predictive ML and DL models are being developed using clinical, morphological, transcriptional and imaging data to assess disease progression and stratify patients by risk, thereby improving prognosis evaluation. Furthermore, AI-driven drug discovery may optimize treatment strategies by identifying novel therapeutic targets, as recently demonstrated with the discovery of an NCK-interacting kinase inhibitor with strong antifibrotic properties. However, several challenges hamper widespread clinical integration and real-life implementation, including data heterogeneity, model interpretability, and the need for robust validation through large-scale, multicenter studies. Future research should prioritize the development of standardized models of AI in large cohorts of IPF patients, combining clinical, imaging, morphologic, multiomics and other data, and enhance model transparency to strengthen clinical confidence. With continued advancements, AI holds potential to improve IPF management, enabling early diagnosis, individualized prognosis, and targeted therapy, all aimed at improving patient outcomes. In this review, we explore the evolving role of AI in IPF management, its potential to support clinical decisions, and the challenges to its clinical integration.

> **中文摘要：**
> 特发性肺纤维化（IPF）是一种病因不明的进行性疾病，其特征为具有典型间质性肺炎放射学和/或形态学模式。其诊断具有一定挑战性，且疾病进展往往存在差异性和不可预测性。近年来，人工智能（AI）的引入，尤其是机器学习（ML）和深度学习（DL）模型，显示出在改善IPF的诊断、预后评估和治疗策略方面的潜力。作为深度学习的一部分，卷积神经网络可提高高分辨率计算机断层扫描（HRCT）分析的准确性，从而促进早期且精确的诊断。同样，基于临床、形态学、转录组及影像学数据的预测性ML和DL模型正在开发，用以评估疾病进展并按风险对患者进行分层，从而改善预后评估。此外，基于AI的药物发现可通过识别新的治疗靶点来优化治疗策略，近期已通过发现一种具有显著抗纤维化特性的NCK相互作用激酶抑制剂得到验证。然而，若干挑战仍阻碍着其在临床的广泛整合与实际应用，包括数据异质性、模型可解释性不足，以及亟需通过大规模、多中心研究进行稳健验证。未来研究应优先发展基于大样本IPF患者的AI标准化模型，整合临床、影像、形态及多组学等多维数据，并提升模型透明度以增强临床信任。随着持续的技术进步，AI有望改善IPF的管理，实现早期诊断、个体化预后评估及靶向治疗，最终提升患者结局。本综述探讨了AI在IPF管理中不断演变的作用、其对临床决策的支持潜力，以及其临床转化所面临的挑战。

### 第二部分 AI 大师评价

该综述系统探讨了人工智能在特发性肺纤维化管理中的应用进展与前景。文章强调了AI在疾病诊断、预后分层及药物发现方面的潜力，尤其是基于影像与多组学数据的ML/DL模型的价值。其创新性在于将多维数据融合与模型透明度提升视为未来关键方向。然而，作者也指出了数据异质性与模型可解释性不足仍是主要限制。总体而言，本文为AI驱动的呼吸疾病精准医学研究提供了重要方向和方法论启示。

---

## 5. 多国队列研究：评估中低收入国家中慢性支气管炎的患病率、危险因素、肺功能及临床结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381225)
**期刊：** The European respiratory journal
**PMID：** 41381225
**DOI：** 10.1183/13993003.01435-2025

### 第一部分 原文与翻译

**英文原标题：** A multi-country cohort study evaluating the prevalence, risk factors, lung function and clinical outcomes of chronic bronchitis in low- and middle-income countries.

> **英文摘要：**
> BACKGROUND: Chronic bronchitis affects up to 40% of individuals with COPD and may serve as an early predictor of the disease and development of COPD. We investigated the prevalence, risk factors, and clinical outcomes associated with chronic bronchitis in three low- and middle-income countries (LMICs).
> 
> METHODS: We conducted a population-based study of adults aged ≥40 years in Bhaktapur (Nepal), Lima (Peru), and Nakaseke (Uganda). Chronic bronchitis was defined as a productive cough several days per week for over four weeks. Multivariable log-binomial regression identified risk factors and outcomes associated with chronic bronchitis.
> 
> RESULTS: Among 9664 participants (mean age 56.2 years, 51.0% male, 66.9% ever smokers), chronic bronchitis prevalence was 9.7%, with 31.5% of those also having COPD. Significant risk factors included older age (adjusted RR=1.54 per 19.8 years, 95% CI 1.4-1.7), male sex (1.18, 1.05-1.34), prior tuberculosis (1.45, 1.14-1.83), prior asthma diagnosis (2.11, 1.84-2.42), pack-years of tobacco use (1.16 per 10 pack-years, 1.14-1.18), family history of chronic respiratory diseases (1.69, 1.50-1.91), second-hand smoke exposure (1.45, 1.28-1.64), lower socioeconomic status quartile (1.22,1.07-1.39), and indoor biomass exposure (1.45, 1.13-1.64). Participants with chronic bronchitis experienced more breathlessness, worse respiratory health (higher St. George's Respiratory Questionnaire scores), and higher hospitalization rates (all p<0.001).
> 
> CONCLUSIONS: Chronic bronchitis is common in LMIC settings and is associated with multiple modifiable risk factors, including second-hand smoke, biomass exposure, and prior respiratory disease. Addressing these factors may reduce disease burden and improve quality of life.

> **中文摘要：**
> 背景：慢性支气管炎影响多达40%的慢性阻塞性肺疾病（COPD）患者，并可能作为该疾病及COPD发展的早期预测指标。我们在三个中低收入国家（LMICs）中调查了慢性支气管炎的患病率、危险因素及其临床结局。
> 
> 方法：我们在尼泊尔巴克塔普尔、秘鲁利马和乌干达纳卡塞克开展了一项基于人群的研究，研究对象为年龄≥40岁的成年人。慢性支气管炎定义为持续4周以上、每周有数天出现咳痰的咳嗽。通过多变量对数二项回归模型识别与慢性支气管炎相关的危险因素和结局。
> 
> 结果：在9664名参与者中（平均年龄56.2岁，男性占51.0%，曾吸烟者占66.9%），慢性支气管炎的患病率为9.7%，其中31.5%的患者同时患有COPD。显著的危险因素包括年龄较大（校正相对风险RR每增加19.8岁为1.54，95%置信区间1.4–1.7）、男性（1.18，1.05–1.34）、既往结核病史（1.45，1.14–1.83）、既往哮喘诊断（2.11，1.84–2.42）、烟草使用包年数（每10包年为1.16，1.14–1.18）、慢性呼吸系统疾病家族史（1.69，1.50–1.91）、二手烟暴露（1.45，1.28–1.64）、较低社会经济地位四分位（1.22，1.07–1.39）以及室内生物质暴露（1.45，1.13–1.64）。患慢性支气管炎者表现出更明显的呼吸困难、更差的呼吸健康状况（圣乔治呼吸问卷得分更高）、以及更高的住院率（均p<0.001）。
> 
> 结论：慢性支气管炎在中低收入国家中常见，并与多种可改变的危险因素相关，包括二手烟暴露、生物质暴露和既往呼吸系统疾病。针对这些因素进行干预可能有助于降低疾病负担并改善生活质量。

### 第二部分 AI 大师评价

本研究通过多国人群队列研究，系统评估了中低收入国家中慢性支气管炎的流行特征及其相关危险因素。研究发现该病患病率较高，且与可干预的环境与行为因素密切相关，如二手烟、生物质暴露和既往呼吸性疾病。研究设计严谨、样本量充足，为全球慢性支气管炎的预防策略提供重要证据。其局限在于横断性设计难以确立因果关系，且结果可能受地区差异影响。

---

## 6. Noonan 综合征患者的肺动脉高压研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381222)
**期刊：** The European respiratory journal
**PMID：** 41381222
**DOI：** 10.1183/13993003.01796-2025

### 第一部分 原文与翻译

**英文原标题：** Pulmonary hypertension in patients with Noonan syndrome.

> **英文摘要：**
> BACKGROUND: Noonan syndrome (NS) is a RASopathy inherited in an autosomal dominant manner, mainly caused by gain-of-function variants activating the RAS/MAPK signalling pathway. Pulmonary hypertension (PH) may occur in NS, but its mechanisms, clinical characteristics, and outcomes remain poorly defined.
> 
> METHODS: We analysed data from the French PH Network to characterize the phenotype of NS patients who develop PH, and conducted a systematic analysis of the literature.
> 
> RESULTS: Seven patients were identified from the French PH Network (male/female ratio: 1.1), with a median age at PH diagnosis of 9 years (range 5-21). Genetic analysis revealed five pathogenic variants in  and one in . Associated features included facial dysmorphism, growth retardation, atrial septal defect and pulmonary valve stenosis. Hemodynamics showed severe precapillary PH without acute vasodilator response: mean pulmonary artery pressure 55 mmHg (40-78), cardiac output 3.95 L.min (3.12-4.95) and pulmonary vascular resistance 13 WU (10-15.3). Computed tomography of the chest identified perivascular ground-glass opacities, mediastinal infiltration, dilated bronchial arteries, distal pulmonary vascular tortuosity and possible arteriovenous shunts. Five patients were treated with drugs approved for PAH. Three patients died and one underwent lung transplantation. Explanted lungs revealed plexiform lesions associated with diffuse lymphangiectasia. Twelve additional cases from the literature included seven with precapillary PH, four with postcapillary PH due to cardiomyopathy, and one without RHC.
> 
> CONCLUSION: Precapillary and postcapillary PH may complicate the course of NS, potentially in association with congenital heart defects and multisystem manifestations. Further studies are needed to better delineate the phenotype of PH in patients with NS.

> **中文摘要：**
> 背景：Noonan 综合征（NS）是一种 RAS 病，呈常染色体显性遗传，主要由激活 RAS/MAPK 信号通路的功能获得性变异所致。NS 可能发生肺动脉高压（PH），但其发病机制、临床特征及结局尚未明确。
> 
> 方法：我们分析了法国肺动脉高压网络的数据，以描述发生 PH 的 NS 患者的表型，并进行了系统的文献综述。
> 
> 结果：从法国肺动脉高压网络中共识别出 7 例患者（男/女比例 1.1），诊断 PH 的中位年龄为 9 岁（范围 5–21 岁）。基因分析显示 5 例携带某基因的致病性变异，1 例携带另一基因的变异。伴随特征包括面部发育异常、生长迟缓、房间隔缺损及肺动脉瓣狭窄。血流动力学检查显示严重的毛细血管前型 PH，且无急性血管扩张反应：平均肺动脉压为 55 mmHg（40–78），心输出量为 3.95 L/min（3.12–4.95），肺血管阻力为 13 WU（10–15.3）。胸部 CT 显示血管周围磨玻璃影、纵隔浸润、支气管动脉扩张、远端肺血管迂曲及可能的动静脉分流。5 名患者接受了肺动脉高压特异性药物治疗，3 名患者死亡，1 名接受肺移植。切除的肺组织显示丛状病变合并弥漫性淋巴管扩张。此外，文献中另有 12 例病例，包括 7 例毛细血管前型 PH、4 例因心肌病导致的毛细血管后型 PH，以及 1 例未进行右心导管检查。
> 
> 结论：毛细血管前型和毛细血管后型肺动脉高压均可使 NS 的病程复杂化，可能与先天性心脏缺陷及多系统表现相关。仍需进一步研究以更清晰界定 NS 患者中 PH 的表型特征。

### 第二部分 AI 大师评价

本研究旨在系统描述 Noonan 综合征患者发生肺动脉高压的临床表型。作者结合法国 PH 网络数据与文献回顾，揭示了该人群中存在毛细血管前型及后型 PH 的异质性。结果显示患者常合并典型的 NS 特征及严重血流动力学异常，部分存在致命结局。该研究为理解 NS 相关 PH 的多样机制提供了关键线索，但受限于病例数较少及基因分布不均，需未来多中心研究验证。

---

## 7. “近期”到底有多近？对可疑“永恒”引用的回顾性分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381096)
**期刊：** BMJ (Clinical research ed.)
**PMID：** 41381096
**DOI：** 10.1136/bmj-2025-086941

### 第一部分 原文与翻译

**英文原标题：** How recent is recent? Retrospective analysis of suspiciously timeless citations.

> **英文摘要：**
> OBJECTIVE: To quantify the time lag between biomedical articles and the studies they describe as "recent," a term widely used to imply timeliness despite rarely reflecting the actual age of the cited evidence.
> 
> DESIGN: Retrospective analysis of suspiciously timeless citations based on a structured PubMed search of 20 predefined "recent" expressions.
> 
> SAMPLE: 1000 English language, full text biomedical articles in which a "recent" expression is directly linked to a citation.
> 
> MAIN OUTCOME MEASURE: Time lag in years between citing articles and their referenced "recent" studies.
> 
> RESULTS: The age of the cited "recent" studies varied widely. The citation lag ranged from 0 to 37 years (mean 5.53 years, median 4 years, interquartile range 2-7). The most frequent lag was one year (n=159, 15.9%), and 177 references (17.7%) were at least 10 years old. Citation patterns varied across medical specialties: critical care, infectious diseases, genetics, immunology, and radiology showed shorter median lags (around two years), while nephrology, veterinary medicine, and dentistry displayed substantially longer lags (ranging from 8.5 to 14 years). Among expressions, "recent approach," "recent discovery," and "recent study" were linked to older references, whereas "recent publication" and "recent article" had much fresher citations. The citation lag was similar across world regions and gradually decreased over time, with the most recent publications showing the shortest lags. Journals with high impact factors (≥12) cited more up-to-date work.
> 
> CONCLUSIONS: This playful analysis suggests that "recent" is applied with striking elasticity across biomedical literature. While some authors cite genuinely recent work, others stretch the definition to decades. Readers and reviewers should take "recent" claims with a grain of chronological salt.

> **中文摘要：**
> 研究目的：量化生物医学论文中引用被称为“近期”的研究与其实际发表时间之间的时间差。“近期”一词广泛用于表示时效性，但很少真正反映被引用证据的实际年代。
> 
> 研究设计：基于结构化的PubMed检索，对20个预定义的“近期”表达式进行了可疑“永恒”引用的回顾性分析。
> 
> 样本：1000篇英文全文生物医学论文，其中“近期”表述直接与某一引用相对应。
> 
> 主要结局指标：引用论文与其所称“近期”研究之间的时间差（以年计）。
> 
> 结果：被引用的“近期”研究年代差异甚大。引用滞后时间范围为0至37年（平均5.53年，中位数4年，四分位间距2–7年）。最常见的滞后为1年（n=159，占15.9%），且有177条引用（17.7%）的研究至少已有10年之久。不同医学专科的引用模式各异：重症医学、感染病学、遗传学、免疫学及放射学的中位引用滞后较短（约2年），而肾脏病学、兽医学及牙医学的滞后显著更长（约8.5至14年）。在不同表述中，“近期方法”“近期发现”“近期研究”往往对应较早的文献，而“近期发表”“近期文章”则引用较新的研究。各地区的引用滞后相似，且随时间推移逐渐缩短，最新发表的文章滞后最小。高影响因子（≥12）的期刊引用的研究总体更为新近。
> 
> 研究结论：这项带有趣味性的分析表明，“近期”一词在生物医学文献中的使用具有显著的弹性。一些作者确实引用了真正的近期工作，而另一些则将“近期”的定义延伸至数十年前。读者与审稿人应对“近期”的表述持适度怀疑的时间观。

### 第二部分 AI 大师评价

该研究以幽默而严谨的方式探讨了生物医学论文中“近期”一词的时间含义，通过系统回顾和定量分析揭示了引用文献的年代与表述之间的偏差。结果显示，不同学科和用语对“近期”的定义差异极大，有些引用甚至可追溯数十年。研究方法学清晰，样本量充分，提示科研写作中语言与事实之间的脱节。其创新性在于将语言使用定量化分析，为科研传播精准性提供了独特视角。

---

## 8. 糖尿病通过激活树突状细胞和γδ T细胞中的CD137L-CD137轴加剧破坏性炎症。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379565)
**期刊：** The Journal of clinical investigation
**PMID：** 41379565
**DOI：** 10.1172/JCI193289

### 第一部分 原文与翻译

**英文原标题：** Diabetes exacerbates destructive inflammation by activating theCD137L-CD137 axis in dendritic and γδ T-cells.

> **英文摘要：**
> Periodontal disease, a bacterial infection affecting a large percentage of the world's population, is an important risk factor for several systemic diseases and is significantly worsened by diabetes. To investigate how diabetes exacerbates the inflammatory response to bacteria in this disease, we combined insights from murine and human studies. Through single-cell RNA sequencing, we identified a compelling hyperglycemia-driven molecular pathway: the upregulation of CD137L in dendritic cells and increased expression of its receptor, CD137, in γδ T-cells. The CD137L-CD137 axis emerged as a pivotal mediator of diabetes-induced inflammatory tissue destruction. Antibody-mediated inhibition of CD137L markedly reduced the diabetes-driven bone loss, neutrophil recruitment, expansion of γδ T-cells, and excessive infiltration by IL17A+ cells. In vitro studies further validated these findings and established that high glucose-mediated dysregulation of dendritic cells dramatically altered γδ T-cell activity in co-culture systems via CD137L. The essential role of dendritic cells as CD137L producers in vivo was definitively established through lineage-specific Akt1 deletion, which abrogated CD137L expression in these cells and reversed the adverse effects of hyperglycemia on leukocyte responses to bacterial pathogens in vivo. Conversely, activation of CD137 with an agonist in normal animals recapitulated diabetes-induced abnormalities in the inflammatory response and accelerated bone loss. These findings elucidate a key mechanism underlying diabetes-induced immune dysregulation and inflammatory damage, and point to the CD137L-CD137 pathway as a promising therapeutic target, offering potential insights into mitigating other diabetes-associated complications linked to inflammatory changes.

> **中文摘要：**
> 牙周病是一种影响全球大量人群的细菌感染性疾病，是多种系统性疾病的重要危险因素，并且在糖尿病的影响下显著加重。为了研究糖尿病如何加剧该疾病中针对细菌的炎症反应，我们结合了小鼠和人类研究的见解。通过单细胞RNA测序，我们鉴定出一个由高血糖驱动的显著分子通路：树突状细胞中CD137L的上调以及γδ T细胞中其受体CD137的表达增加。CD137L-CD137轴被确认为糖尿病诱导的炎症性组织破坏的关键介导因子。抗体介导的CD137L抑制显著减少了糖尿病驱动的骨丧失、中性粒细胞募集、γδ T细胞扩增及IL17A+细胞的过度浸润。体外研究进一步验证了这些发现，并证实高糖介导的树突状细胞失调通过CD137L在共培养系统中剧烈改变了γδ T细胞的活性。通过系谱特异性删除Akt1从而消除这些细胞中的CD137L表达，明确证实了树突状细胞作为体内CD137L产生者的关键作用，并逆转了高血糖对体内白细胞应对细菌病原体反应的不利影响。相反，在正常动物中使用激动剂激活CD137可重现糖尿病所致的炎症反应异常并加速骨丧失。这些发现阐明了糖尿病诱发免疫失调和炎症损伤的关键机制，并指出CD137L-CD137通路是一个有前景的治疗靶点，为缓解其他与糖尿病相关的炎症性并发症提供了潜在的新思路。

### 第二部分 AI 大师评价

本研究旨在揭示糖尿病加剧炎症性组织破坏的免疫学机制。作者利用小鼠与人类样本结合单细胞RNA测序，发现高血糖驱动的CD137L-CD137信号轴在树突状细胞与γδ T细胞间介导了糖尿病相关的免疫失衡。抗体阻断和基因删除实验均验证了CD137L在炎症放大中的关键作用，并通过激动剂模型进一步证明该通路的病理效应。研究创新性地揭示了糖尿病对固有免疫-适应性免疫交互的影响，为糖尿病相关炎症性并发症的靶向干预提供了新方向，但仍需临床转化研究以确认其可行性。

---

## 9. CD14CD163HLA-DR 单核细胞的转录组可预测特发性肺纤维化的死亡率

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360505)
**期刊：** The European respiratory journal
**PMID：** 41360505
**DOI：** 10.1183/13993003.00804-2025

### 第一部分 原文与翻译

**英文原标题：** The transcriptome of CD14CD163HLA-DR monocytes predicts mortality in Idiopathic Pulmonary Fibrosis.

> **英文摘要：**
> BACKGROUND: The association between immune-cell-specific transcriptomic profiles and mortality in IPF is unknown.
> 
> METHODS: We profiled peripheral blood mononuclear cells (PBMC) by single-cell RNA sequencing (scRNA-seq) and investigated which immune-cell-specific transcriptomic profile predicted IPF outcomes consistently. Prognostic accuracy was investigated in PBMC, Bronchoalveolar Lavage (BAL) and lung tissue. Findings were validated by flow cytometry, analysis of independent scRNA-seq datasets and cellular deconvolution. We investigated the function of this transcriptomic profile and its cellular source in lung tissue (overall sample size:1054, IPF:555, other:499). Connectivity map and LASSO regression were used to identify drug candidates and a subset of genes with prognostic potential, respectively.
> 
> RESULTS: A 230-gene-up-score (Pittsburgh-PBMC) from CD14CD163HLA-DR monocytes predicted mortality in Chicago PBMC cohort (HR: 6.58, 95%CI:2.15-20.13, p=0.001), in BAL pooled analysis (HR: 2.20, 95%CI: 1.44-3.37, p=0.0003) and negatively correlated with Forced Vital Capacity (FVC) in lung tissues (ρ=-0.2, p=0.02). CD14CD163HLA-DR monocytes were higher in progressive  stable IPF (12.59%, 95%CI:9.66-16.23,  7.61%, 95%CI:6.68-10.21, p=0.014). High risk IPF patients had decreased expression of T-cell co-stimulatory genes (Pittsburgh and Chicago p<0.01). CD14HLA-DR monocytes had higher expression of profibrotic, proangiogenic and chemotactic factors compared to CD14HLA-DR monocytes (p<0.05). The 230-gene-up-score correlated with the SPP1fibrosis-associated macrophages-gene-score in lung tissues (ρ=0.19, p<2.2e16). Connectivity map identified drug categories to reverse the 230-gene-signature. A subset of six genes retained predictive performance (pooled PBMC cohorts -HR: 4.79, 95%CI:2.58-8.92, p<0.0001).
> 
> CONCLUSIONS: The transcriptome of CD14CD163HLA-DR monocytes is associated with increased mortality in patients with IPF. Its reversal should be investigated as a precision-based therapy in IPF.

> **中文摘要：**
> 背景：目前尚不清楚免疫细胞特异性转录组特征与特发性肺纤维化（IPF）死亡率之间的关联。
> 
> 方法：我们利用单细胞 RNA 测序（scRNA-seq）对外周血单个核细胞（PBMC）进行转录组分析，并探讨哪种免疫细胞特异性转录组特征能够持续预测 IPF 的结局。预后准确性在 PBMC、支气管肺泡灌洗液（BAL）和肺组织中进行了验证。研究结果通过流式细胞术、独立 scRNA-seq 数据集分析及细胞分解方法进行验证。同时，我们评估了该转录组特征的功能及其在肺组织中的细胞来源（总体样本量：1054例，其中 IPF：555例，其他：499例）。使用 Connectivity Map 和 LASSO 回归分别用于鉴定潜在药物候选物和具有预后潜力的基因子集。
> 
> 结果：来自 CD14CD163HLA-DR 单核细胞的 230 基因上调评分（Pittsburgh-PBMC）在芝加哥 PBMC 队列中可预测死亡（危险比 HR：6.58，95%CI：2.15-20.13，p=0.001），在 BAL 合并分析中同样具有显著性（HR：2.20，95%CI：1.44-3.37，p=0.0003），并与肺组织中的用力肺活量（FVC）呈负相关（ρ=-0.2，p=0.02）。CD14CD163HLA-DR 单核细胞在进展性 IPF 患者中比例高于稳定型 IPF（12.59%，95%CI：9.66-16.23 vs 7.61%，95%CI：6.68-10.21，p=0.014）。高风险 IPF 患者的 T 细胞共刺激基因表达下降（Pittsburgh 和 Chicago 均 p<0.01）。与 CD14HLA-DR 单核细胞相比，CD14CD163HLA-DR 单核细胞具有更高水平的促纤维化、促血管生成及趋化因子表达（p<0.05）。230 基因上调评分与肺组织中的 SPP1 纤维化相关巨噬细胞基因评分呈相关（ρ=0.19，p<2.2e-16）。Connectivity Map 分析发现了可逆转该基因特征的药物类别。六个基因组成的子集在合并 PBMC 队列中仍保留预测能力（HR：4.79，95%CI：2.58-8.92，p<0.0001）。
> 
> 结论：CD14CD163HLA-DR 单核细胞的转录组与 IPF 患者的较高死亡率相关。其逆转值得作为精准治疗方向进行探索。

### 第二部分 AI 大师评价

该研究系统解析了 IPF 患者中 CD14CD163HLA-DR 单核细胞的转录组特征，并揭示其与死亡率的显著关联。通过多队列的单细胞 RNA 测序、流式验证及综合生物信息学分析，研究确立了 230 基因上调特征的预后价值，并筛选出潜在治疗靶点。研究创新性在于将免疫细胞特征与临床预后直接关联，为精准治疗提供新方向。局限性可能在于尚需前瞻性验证及功能研究确认。

---

## 10. NUDT5 通过与 PPAT 相互作用调控嘌呤代谢及硫嘌呤敏感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41196949)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196949
**DOI：** 10.1126/science.adx9717

### 第一部分 原文与翻译

**英文原标题：** NUDT5 regulates purine metabolism and thiopurine sensitivity by interacting with PPAT.

> **英文摘要：**
> Cells generate purine nucleotides through de novo purine biosynthesis (DNPB) and purine salvage. Purine salvage represses DNPB to prevent excessive purine nucleotide synthesis through mechanisms that are incompletely understood. We identified Nudix hydrolase 5 (NUDT5) as a DNPB regulator. During purine salvage, NUDT5 suppresses DNPB independently of its catalytic function but rather through interaction with phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme in the DNPB pathway. The NUDT5-PPAT interaction promoted PPAT oligomerization, suppressed PPAT's enzymatic activity, and facilitated disassembly of the purinosome, a metabolon that functions in DNPB. Disrupting the NUDT5-PPAT interaction overcame DNPB suppression during purine salvage, permitting excessive DNPB and inducing thiopurine resistance. Therefore, NUDT5 governs the balance between DNPB and salvage to maintain appropriate cellular purine nucleotide concentrations.

> **中文摘要：**
> 细胞通过从头嘌呤合成（DNPB）和嘌呤再利用途径生成嘌呤核苷酸。嘌呤再利用途径会抑制 DNPB，以防止过量嘌呤核苷酸的合成，但其机制尚不完全清楚。我们鉴定出 Nudix 水解酶 5（NUDT5）为 DNPB 的一个调控因子。在嘌呤再利用过程中，NUDT5 并非通过其催化功能，而是通过与磷酸核糖焦磷酸转氨酶（PPAT，DNPB 通路中的限速酶）的相互作用来抑制 DNPB。NUDT5-PPAT 的相互作用促进了 PPAT 的聚合，抑制了其酶活性，并促进了在 DNPB 中发挥作用的嘌呤小体（purinosome）的解体。破坏 NUDT5 与 PPAT 之间的相互作用会解除嘌呤再利用过程中的 DNPB 抑制，从而导致 DNPB 过度活跃并引起硫嘌呤耐药。因此，NUDT5 通过调节 DNPB 与嘌呤再利用之间的平衡，维持细胞内适当的嘌呤核苷酸浓度。

### 第二部分 AI 大师评价

本研究揭示了 NUDT5 通过与 PPAT 的非催化性相互作用调控从头嘌呤合成与嘌呤再利用之间平衡的关键机制。研究团队利用生化和分子机制分析发现，NUDT5 可通过影响 PPAT 寡聚化与嘌呤小体组装，精细控制细胞内嘌呤合成活动。结果阐明了嘌呤代谢稳态的新调控层次，并关联硫嘌呤药物敏感性，为代谢调控与耐药性研究提供了新的分子靶点。然而，机制是否具有组织或病理条件特异性仍需进一步探索。

---

## 11. 机械敏感性基因增强子强化细胞对基质刚度的响应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40997217)
**期刊：** Science (New York, N.Y.)
**PMID：** 40997217
**DOI：** 10.1126/science.adl1988

### 第一部分 原文与翻译

**英文原标题：** Mechanosensitive genomic enhancers potentiate the cellular response to matrix stiffness.

> **英文摘要：**
> Epigenetic control of gene expression and cellular phenotype is influenced by changes in the local microenvironment, yet how mechanical cues precisely influence epigenetic state to regulate transcription remains largely unmapped. In this study, we combined genome-wide epigenome profiling, epigenome editing, and phenotypic and single-cell RNA sequencing CRISPR screening to identify a class of genomic enhancers that responds to the mechanical microenvironment. These "mechanoenhancers" can be preferentially activated on either soft or stiff extracellular matrix contexts and regulate transcription to influence critical cell functions including apoptosis, adhesion, proliferation, and migration. Epigenetic editing of mechanoenhancers reprograms the cellular response to the mechanical microenvironment and modulates the activation of disease-related genes in lung fibroblasts from healthy and fibrotic donors. Epigenetic editing of mechanoenhancers holds potential for precise targeting of mechanically driven diseases.

> **中文摘要：**
> 基因表达和细胞表型的表观遗传调控受局部微环境变化的影响，但机械信号如何精确地影响表观遗传状态以调控转录尚未得到系统映射。在本研究中，我们结合了全基因组范围的表观基因组分析、表观基因组编辑，以及基于表型和单细胞RNA测序的CRISPR筛选，鉴定出一类对机械性微环境有响应的基因增强子。这些“机械增强子”可在柔软或坚硬的细胞外基质环境中被选择性激活，并通过调控转录影响包括细胞凋亡、黏附、增殖和迁移在内的关键细胞功能。对机械增强子的表观遗传编辑能够重塑细胞对机械微环境的响应，并调节来自健康和纤维化供体的肺成纤维细胞中疾病相关基因的激活。机械增强子的表观遗传编辑有望实现对机械驱动性疾病的精准干预。

### 第二部分 AI 大师评价

该研究旨在揭示机械信号如何通过表观遗传机制调控基因转录与细胞命运。研究团队运用全基因组表观分析、CRISPR筛选与表观编辑等多维方法，发现了一类对基质刚度敏感的“机械增强子”，能够调节多种关键细胞功能。此发现首次系统连接了机械微环境与染色质调控网络，具有潜在的转化医学价值。虽需进一步探索其在不同组织和疾病模型中的普适性，但该工作在机械生物学与表观遗传学交叉领域开辟了新方向。

---

速递结束，祝您工作愉快！